NCT02993757View on ClinicalTrials.gov

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

PHASE3CompletedINTERVENTIONAL
Enrollment

528

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

May 27, 2019

Study Completion Date

May 27, 2019

Conditions
Dengue FeverDengue Hemorrhagic FeverHuman Papillomavirus Disease
Interventions
BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.

BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, SC injection at Month 1, 7 and 13, respectively.

BIOLOGICAL

Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.

0.5 mL, IM injection at Day 0 and Month 6, respectively.

Trial Locations (5)

25100

Sanofi Pasteur Investigational Site 003, Kuantan

42000

Sanofi Pasteur Investigational Site 004, Klang

50590

Sanofi Pasteur Investigational Site 005, Kuala Lumpur

59100

Sanofi Pasteur Investigational Site 001, Kuala Lumpur

96000

Sanofi Pasteur Investigational Site 002, Sibu

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02993757 - Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® | Biotech Hunter | Biotech Hunter